表紙
市場調查報告書
商品編碼
1030175

動物用疫苗的全球市場-各類型、各動物類型:機會分析及產業預測(2021年∼2030年)

Animal Vaccines Market by Type and Animal Type : Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日期: | 出版商: Allied Market Research | 英文 234 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球動物用疫苗市場規模,2020年達到了90億9,390萬美元。

2028年達到137億8,060萬美元,從2021年到2028年之間以5.3%的年複合成長率成長。

由於全球寵物的引進,對家畜和寵物的健康意識高漲,在預測期間內預計緩慢成長。肉和牛奶的消費量增加,人獸共通感染疾病的發生等推動動物用疫苗市場成長。

可是,對有關疫苗的製造和保管的成本高,及對動物的不必要過度投藥妨礙市場成長。再加上寵物飼主之間對動物福利相關意識低,也阻礙動物用疫苗市場擴大。

本報告提供全球動物用疫苗市場的相關調查,市場概要,市場動態,市場分析,企業簡介等全面性資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 主要的成功策略
    • 主要的投資口袋
  • 政府的法規
    • 獸醫生物中心(CVB)
  • 主要企業的定位
  • 波特的五力分析
  • 市場動態
    • 促進因素
      • 寵物保險的需求的成長
      • 動物的病的盛行率增加
      • 寵物的所有者增加
      • 動物的健康支出增加
    • 阻礙因素
      • 競爭激烈的肉和牛奶的價格
      • 獸醫用疫苗對人和動物的健康的不良影響
    • 市場機會
      • 疫苗產品的進步
      • 雜種動物的需求增加
  • 市場上的COVID-19的影響分析
  • mRNA動物疫苗臨床分析
  • 價格分析

第4章 動物用疫苗市場:各類型

  • 概要
    • 市場規模與預測
  • 弱毒化疫苗
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測
    • 市場分析:各國
  • 不活化疫苗
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測
    • 市場分析:各國
  • 次單元疫苗
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測
    • 市場分析:各國
  • 類毒素疫苗
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測
    • 市場分析:各國
  • 結合型疫苗
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測
    • 市場分析:各國
  • 重組疫苗
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測
    • 市場分析:各國
  • DNA疫苗
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測
    • 市場分析:各國

第5章 動物用疫苗市場:各動物類型

  • 概要
    • 市場規模與預測
  • 寵物
    • 市場規模與預測:各類型
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 家畜
      • 家禽
      • 綿羊
      • 其他
  • 養殖
    • 市場規模與預測
    • 市場規模與預測:按疾病
    • 市場分析:各國

第6章 動物用疫苗市場:各地區

  • 概要
    • 市場規模與預測
  • 北美
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測:各產品
    • 市場規模與預測:各動物類型
    • 市場規模與預測:各國
      • 美國的市場規模與預測:各產品
      • 美國的市場規模與預測:各動物類型
      • 加拿大的市場規模與預測:各產品
      • 加拿大的市場規模與預測:各動物類型
      • 墨西哥的市場規模與預測:各產品
      • 墨西哥的市場規模與預測:各動物類型
  • 歐洲
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測:各產品
    • 市場規模與預測:各動物類型
    • 市場規模與預測:各國
      • 德國的市場規模與預測:各產品
      • 德國的市場規模與預測:各動物類型
      • 法國的市場規模與預測:各產品
      • 法國的市場規模與預測:各動物類型
      • 英國的市場規模與預測:各產品
      • 英國的市場規模與預測:各動物類型
      • 義大利的市場規模與預測:各產品
      • 義大利的市場規模與預測:各動物類型
      • 其他的市場規模與預測:各產品
      • 其他的市場規模與預測:各動物類型
  • 亞太地區
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測:各產品
    • 市場規模與預測:各動物類型
    • 市場規模與預測:各國
      • 日本的市場規模與預測:各產品
      • 日本的市場規模與預測:各動物類型
      • 中國的市場規模與預測:各產品
      • 中國的市場規模與預測:各動物類型
      • 澳洲的市場規模與預測:各產品
      • 澳洲的市場規模與預測:各動物類型
      • 印度的市場規模與預測:各產品
      • 印度的市場規模與預測:各動物類型
      • 韓國的市場規模與預測:各產品
      • 韓國的市場規模與預測:各動物類型
      • 其他的市場規模與預測:各產品
      • 其他的市場規模與預測:各動物類型
  • 南美、中東、非洲
    • 主要的市場趨勢,主要的成長因素及機會
    • 市場規模與預測:各產品
    • 市場規模與預測:各動物類型
    • 市場規模與預測:各國
      • 巴西的市場規模與預測:各產品
      • 巴西的市場規模與預測:各動物類型
      • 沙烏地阿拉伯的市場規模與預測:各產品
      • 沙烏地阿拉伯的市場規模與預測:各動物類型
      • 其他的市場規模與預測:各產品
      • 其他的市場規模與預測:各動物類型

第7章 企業簡介

  • ANICON LABOR GMBH
  • BOEHRINGER INGELHEIM GMBH
  • CEVA SANTE ANIMALE
  • HYGIEIA BIOLOGICAL LABORATORIES
  • MERCK & COMPANY INC.
  • ROMVAC COMPANY S.A.
  • SANOFI S.A.
  • VAXXINOVA GMBH
  • VIRBAC S.A
  • ZOETIS INC.
目錄
Product Code: A01658

Veterinary vaccines play a significant role in the protection of animal and public health, ensuring efficacy in the productivity of food animal sufficing the feed of ever-increasing human population. Animal vaccines have also reduced the risks posed by heavy dosage of antibiotics to food and companion animal. Veterinary vaccinations not only benefit animal health but also have a major effect on the public health by aiding in elimination of zoonotic diseases, which transmit from animal to humans. Injecting against rabies vaccines in domestic animal and wildlife helped in maximum elimination of human rabies in the developed countries. Developments in the genetic engineering technology have led to the production of new vaccines such as gene-deleted marker vaccines, virus-like-particle vaccines, recombinant modified live virus vaccines, chimeric vaccines, and DNA vaccines. Utilization of animal vaccines on large scale is necessary to enable effective control of animal diseases and requires vaccines to be available at affordable prices. Technological advancements in vaccine technology helps achieve reduction in the cost of veterinary vaccines.

The global animal vaccines market was valued at $9,093.9 million in 2020, and is projected to reach $13,780.6 million by 2028, registering a CAGR of 5.3% from 2021 to 2028. The market is expected to witness moderate growth during the forecast period, owing to the increase in adoption of companion animal worldwide and rise in the awareness about animal health with respect to livestock and pet animal. In addition, increase in meat and milk consumption and rise in the emergence of zoonotic diseases supplement the animal vaccines market growth. However, high cost of vaccine production and storage and unnecessary excessive vaccine administration to animal hamper the market growth. Moreover, lack of awareness regarding animal welfare among pet owners hinders the expansion of the animal vaccines market.

The animal vaccines market is segmented on the basis of product type, animal type, and region. By product type, the market is categorized into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. By animal type, the market is segmented into companion animal, livestock animal, and aquaculture. The companion animal segment is further segmented into cats and dogs. The livestock animal segment is further classified into cattle, pigs, poultry, sheep, and others (goats, horses, asses, camel, and others). By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global animal vaccines market trends from 2020 to 2028 to identify the prevailing opportunities along with the strategic assessment.
  • The global animal vaccines market forecast is studied from 2021 to 2028.
  • The animal vaccines market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global animal vaccines market.

KEY MARKET SEGMENTS

By Type

  • Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Conjugate Vaccines
  • Recombinant Vaccines
  • DNA Vaccines

By Animal Type

  • Companion animal
  • Dogs
  • Cats
  • Livestock animal
  • Cattle
  • Pigs
  • Poultry
  • Sheep
  • Others
  • Aquaculture

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Merck & Co.
  • Zoetis Inc.
  • Ceva Sante Animale
  • Sanofi S.A.
  • Romvac
  • Vaxxinova GmbH
  • Biovac
  • Anicon Labor GmbH
  • Merial
  • Boehringer Ingelheim GmbH

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits to the stakeholders
  • 1.3.Key market segments
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top winning strategies
    • 3.2.2.Top investment pockets
  • 3.3.Government Regulations
    • 3.3.1.Center for Veterinary Biologics (CVB)
  • 3.4.Top player positioning
  • 3.5.Porter's five forces analysis
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Growth in demand for pet insurance
      • 3.6.1.2.Increase in prevalence of animal diseases
      • 3.6.1.3.Growth in ownership of companion animal
      • 3.6.1.4.Rise in animal health expenditure
    • 3.6.2.Restraints
      • 3.6.2.1.Highly competitive meat and milk prices
      • 3.6.2.2.Adverse impact of veterinary vaccines on human and animal health
    • 3.6.3.Opportunities
      • 3.6.3.1.Advancement in vaccine products
      • 3.6.3.2.Increase in demand for hybrid animal
  • 3.7.COVID-19 Impact Analysis on the market
  • 3.8.mRNA animal vaccine clinical analysis
  • 3.9.Pricing analysis

CHAPTER 4:ANIMAL VACCINES MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Attenuated Vaccines
    • 4.2.1.Key market trends, key growth factors and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.Inactivated Vaccines
    • 4.3.1.Key market trends, key growth factors and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Subunit Vaccines
    • 4.4.1.Key market trends, key growth factors and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Toxoid Vaccines
    • 4.5.1.Key market trends, key growth factors and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country
  • 4.6.Conjugate Vaccines
    • 4.6.1.Key market trends, key growth factors and opportunities
    • 4.6.2.Market size and forecast
    • 4.6.3.Market analysis, by country
  • 4.7.Recombinant Vaccines
    • 4.7.1.Key market trends, key growth factors and opportunities
    • 4.7.2.Market size and forecast
    • 4.7.3.Market analysis, by country
  • 4.8.DNA Vaccines
    • 4.8.1.Key market trends, key growth factors and opportunities
    • 4.8.2.Market size and forecast
    • 4.8.3.Market analysis, by country

CHAPTER 5:ANIMAL VACCINES MARKET, BY ANIMAL TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Companion animal
    • 5.2.1.Market size and forecast, by type
      • 5.2.1.1.Dogs
      • 5.2.1.1.1.Market size and forecast
      • 5.2.1.1.2. Market size and forecast, by disease
      • 5.2.1.2.Cats
      • 5.2.1.2.1.Market size and forecast
      • 5.2.1.2.2. Market size and forecast, by disease
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Livestock Animal
      • 5.3.1.1.Cattle
      • 5.3.1.1.1.Market size and forecast
      • 5.3.1.1.2. Market size and forecast, by disease
      • 5.3.1.2.Pigs
      • 5.3.1.2.1.Market size and forecast
      • 5.3.1.2.2. Market size and forecast, by disease
      • 5.3.1.3.Poultry
      • 5.3.1.3.1.Market size and forecast
      • 5.3.1.3.2. Market size and forecast, by disease
      • 5.3.1.4.Sheep
      • 5.3.1.4.1.Market size and forecast
      • 5.3.1.4.2. Market size and forecast, by disease
      • 5.3.1.5.Horses
      • 5.3.1.5.1.Market size and forecast
      • 5.3.1.5.2.Market size and forecast, by disease
      • 5.3.1.6.Others
      • 5.3.1.6.1.Market size and forecast
      • 5.3.1.6.2. Market size and forecast, by disease
  • 5.4.Aquaculture
    • 5.4.1.Market size and forecast
    • 5.4.2.Market size and forecast, by disease
    • 5.4.3.Market analysis, by country

CHAPTER 6:ANIMAL VACCINES MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, key growth factors and opportunities
    • 6.2.2.Market size and forecast, by product
    • 6.2.3.Market size and forecast, by animal type
    • 6.2.4.Market size and forecast, by country
      • 6.2.4.1.U.S. market size and forecast, by product
      • 6.2.4.2.U.S. market size and forecast, by animal type
      • 6.2.4.3.Canada market size and forecast, by product
      • 6.2.4.4.Canada market size and forecast, by animal type
      • 6.2.4.5.Mexico market size and forecast, by product
      • 6.2.4.6.Mexico market size and forecast, by animal type
  • 6.3.Europe
    • 6.3.1.Key market trends, key growth factors and opportunities
    • 6.3.2.Market size and forecast, by product
    • 6.3.3.Market size and forecast, by animal type
    • 6.3.4.Market size and forecast, by country
      • 6.3.4.1.Germany market size and forecast, by product
      • 6.3.4.2.Germany market size and forecast, by animal type
      • 6.3.4.3.France market size and forecast, by product
      • 6.3.4.4.France market size and forecast, by animal type
      • 6.3.4.5.UK market size and forecast, by product
      • 6.3.4.6.UK market size and forecast, by animal type
      • 6.3.4.7.Italy market size and forecast, by product
      • 6.3.4.8.Italy market size and forecast, by animal type
      • 6.3.4.9.Rest of Europe market size and forecast, by product
      • 6.3.4.10.Rest of Europe market size and forecast, by animal type
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, key growth factors and opportunities
    • 6.4.2.Market size and forecast, by product
    • 6.4.3.Market size and forecast, by animal type
    • 6.4.4.Market size and forecast, by country
      • 6.4.4.1.Japan market size and forecast, by product
      • 6.4.4.2.Japan market size and forecast, by animal type
      • 6.4.4.3.China market size and forecast, by product
      • 6.4.4.4.China market size and forecast, by animal type
      • 6.4.4.5.Australia market size and forecast, by product
      • 6.4.4.6.Australia market size and forecast, by animal type
      • 6.4.4.7.India market size and forecast, by product
      • 6.4.4.8.India market size and forecast, by animal type
      • 6.4.4.9.South Korea market size and forecast, by product
      • 6.4.4.10.South Korea market size and forecast, by animal type
      • 6.4.4.11.Rest of Asia-Pacific market size and forecast, by product
      • 6.4.4.12.Rest of Asia-Pacific market size and forecast, by animal type
  • 6.5.LAMEA
    • 6.5.1.Key market trends, key growth factors and opportunities
    • 6.5.2.Market size and forecast, by product
    • 6.5.3.Market size and forecast, by animal type
    • 6.5.4.Market size and forecast, by country
      • 6.5.4.1.Brazil market size and forecast, by product
      • 6.5.4.2.Brazil market size and forecast, by animal type
      • 6.5.4.3.Saudi Arabia market size and forecast, by product
      • 6.5.4.4.Saudi Arabia market size and forecast, by animal type
      • 6.5.4.5.Rest of LAMEA market size and forecast, by product
      • 6.5.4.6.Rest of LAMEA market size and forecast, by animal type

CHAPTER 7:COMPANY PROFILES

  • 7.1.ANICON LABOR GMBH
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
  • 7.2.BOEHRINGER INGELHEIM GMBH
    • 7.2.1.Company overview
    • 7.2.2.Operating business segments
    • 7.2.3.Product portfolio
    • 7.2.4.Business performance
    • 7.2.5.Key strategic moves and developments
  • 7.3.CEVA SANTE ANIMALE
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Product portfolio
    • 7.3.4.Key strategic moves and developments
  • 7.4.HYGIEIA BIOLOGICAL LABORATORIES
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
  • 7.5.MERCK & COMPANY INC.
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.ROMVAC COMPANY S.A.
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
  • 7.7.SANOFI S.A.
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
    • 7.7.6.Key strategic moves and developments
  • 7.8.VAXXINOVA GMBH
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Key strategic moves and developments
  • 7.9.VIRBAC S.A
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
  • 7.10.ZOETIS INC.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves & developments

LIST OF TABLES

  • TABLE 01.NUMBER OF U.S. HOUSEHOLDS THAT OWN A PET, BY TYPE OF ANIMAL (MILLION)
  • TABLE 02.POPULATION OF DOGS AND CATS IN EUROPEAN COUNTRIES, 2019
  • TABLE 03.MRNA ANIMAL VACCINE: CLINICAL ANALYSIS
  • TABLE 04.NORTH AMERICA: ANIMAL VACCINES PRICES
  • TABLE 05.EUROPE: ANIMAL VACCINES PRICES
  • TABLE 06.ASIA-PACIFIC: ANIMAL VACCINES PRICES
  • TABLE 07.LAMEA: ANIMAL VACCINES PRICES
  • TABLE 08.ANIMAL VACCINES MARKET, BY PRODUCT TYPE 2020-2030, ($MILLION)
  • TABLE 09.ANIMAL VACCINES MARKET FOR ATTENUATED VACCINES BY REGION 2020-2030, ($MILLION)
  • TABLE 10.ANIMAL VACCINES MARKET FOR INACTIVATED VACCINES BY REGION 2020-2030, ($MILLION)
  • TABLE 11.ANIMAL VACCINES MARKET FOR SUBUNIT VACCINES BY REGION 2020-2030, ($MILLION)
  • TABLE 12.ANIMAL VACCINES MARKET FOR TOXOID VACCINES BY REGION 2020-2030, ($MILLION)
  • TABLE 13.ANIMAL VACCINES MARKET FOR CONJUGATE VACCINES BY REGION 2020-2030, ($MILLION)
  • TABLE 14.ANIMAL VACCINES MARKET FOR RECOMBINANT VACCINES BY REGION 2020-2030, ($MILLION)
  • TABLE 15.ANIMAL VACCINES MARKET FOR DNA VACCINES BY REGION 2020-2030, ($MILLION)
  • TABLE 16.ANIMAL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 17.COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 18.VACCINATION FOR DOGS: CORE AND NON-CORE
  • TABLE 19.ANIMAL VACCINES MARKET FOR DOGS, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 20.VACCINATION FOR CATS: CORE AND NON-CORE
  • TABLE 21.ANIMAL VACCINES MARKET FOR CATS, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 22.COMPANION ANIMAL VACCINES MARKET, BY REGION, 2020-2030, ($MILLION)
  • TABLE 23.LIVESTOCK ANIMAL VACCINES MARKET, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 24.ANIMAL VACCINES MARKET FOR CATTLE, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 25.TOP 5 PORK CONSUMING COUNTRIES, 2020
  • TABLE 26.ANIMAL VACCINES MARKET FOR PIGS, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 27.TOP 5 POULTRY CONSUMING COUNTRIES, 2020
  • TABLE 28.ANIMAL VACCINES MARKET FOR POULTRY, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 29.TOP 5 SHEEP MEAT CONSUMING COUNTRIES, 2020
  • TABLE 30.ANIMAL VACCINES MARKET FOR SHEEP, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 31.ANIMAL VACCINES MARKET FOR HORSES, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 32.LIVESTOCK ANIMAL VACCINES MARKET, BY REGION, 2020-2030, ($MILLION)
  • TABLE 33.AQUACULTURE ANIMAL VACCINES MARKET, BY REGION, 2020-2030, ($MILLION)
  • TABLE 34.ANIMAL VACCINES MARKET FOR AQUACULTURE, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 35.ANIMAL VACCINES MARKET, BY REGION 2020-2030, ($MILLION)
  • TABLE 36.NORTH AMERICA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 37.NORTH AMERICA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 38.NORTH AMERICA ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
  • TABLE 39.U.S. ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 40.U.S. ANIMAL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 41.CANADA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 42.CANADA ANIMAL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 43.MEXICO ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 44.MEXICO VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 45.EUROPE ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 46.EUROPE VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 47.EUROPE ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
  • TABLE 48.GERMANY ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 49.GERMANY VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 50.FRANCE ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 51.FRANCE VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 52.UK ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 53.UK VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 54.ITALY ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 55.ITALY VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 56.REST OF EUROPE ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 57.REST OF EUROPE VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 58.ASIA-PACIFIC ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 59.ASIA-PACIFIC VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 60.ASIA-PACIFIC ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
  • TABLE 61.JAPAN ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 62.JAPAN VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 63.CHINA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 64.CHINA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 65.AUSTRALIA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 66.AUSTRALIA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 67.INDIA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 68.INDIA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 69.SOUTH KOREA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 70.SOUTH KOREA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 73.LAMEA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 74.LAMEA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 75.LAMEA ANIMAL VACCINES MARKET, BY COUNTRY, 2020-2030, ($MILLION)
  • TABLE 76.BRAZIL ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 77.BRAZIL VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 78.SAUDI ARABIA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 79.SAUDI ARABIA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 80.REST OF LAMEA ANIMAL VACCINES MARKET, BY PRODUCT, 2020-2030, ($MILLION)
  • TABLE 81.REST OF LAMEA VACCINES MARKET, BY ANIMAL TYPE, 2020-2030, ($MILLION)
  • TABLE 82.ANICON: COMPANY SNAPSHOT
  • TABLE 83.ANICON: OPERATING SEGMENTS
  • TABLE 84.ANICON: PRODUCT PORTFOLIO
  • TABLE 85.BOEHRINGER: COMPANY SNAPSHOT
  • TABLE 86.BOEHRINGER: OPERATING SEGMENTS
  • TABLE 87.BOEHRINGER: PRODUCT PORTFOLIO
  • TABLE 88.CEVA : COMPANY SNAPSHOT
  • TABLE 89.CEVA : PRODUCT PORTFOLIO
  • TABLE 90.HYGIEIA: COMPANY SNAPSHOT
  • TABLE 91.HYGIEIA: OPERATING SEGMENTS:
  • TABLE 92.HYGIEIA: PRODUCT PORTFOLIO
  • TABLE 93.MERCK: COMPANY SNAPSHOT
  • TABLE 94.MERCK: OPERATING SEGMENTS
  • TABLE 95.MERCK: PRODUCT PORTFOLIO
  • TABLE 96.ROMVAC: COMPANY SNAPSHOT
  • TABLE 97.ROMVAC: OPERATING SEGMENTS
  • TABLE 98.ROMVAC: PRODUCT PORTFOLIO
  • TABLE 99.SANOFI: COMPANY SNAPSHOT
  • TABLE 100.SANOFI: OPERATING SEGMENTS
  • TABLE 101.SANOFI: PRODUCT PORTFOLIO
  • TABLE 102.VAXXINOVA: COMPANY SNAPSHOT
  • TABLE 103.VAXXINOVA: OPERATING SEGMENTS
  • TABLE 104.VAXXINOVA: PRODUCT PORTFOLIO
  • TABLE 105.VIRBAC: COMPANY SNAPSHOT
  • TABLE 106.VIRBAC: OPERATING SEGMENTS
  • TABLE 107.VIRBAC: PRODUCT PORTFOLIO
  • TABLE 108.ZOETIS: COMPANY SNAPSHOT
  • TABLE 109.ZOETIS: OPERATING SEGMENTS
  • TABLE 110.ZOETIS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2018-2021*)
  • FIGURE 02.TOP WINNING STRATEGIES: BY DEVELOPMENT (2018-2021*)
  • FIGURE 03.TOP WINNING STRATEGIES: BY COMPANY (2018-2021*)
  • FIGURE 04.TOP INVESTMENT POCKETS: ANIMAL VACCINES MARKET
  • FIGURE 05.TOP PLAYER POSITIONING, 2020
  • FIGURE 06.LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTION
  • FIGURE 09.MODERATE THREAT OF NEW ENTRANT
  • FIGURE 10.HIGH COMPETITIVE RIVALRY
  • FIGURE 11.DRIVERS, RESTRAINTS & OPPORTUNITIES
  • FIGURE 12.U.S. PET INDUSTRY EXPENDITURE, 2010-2019 ($BILLION)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR ATTENUATED VACCINES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR SUBUNIT VACCINES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ANIMAL VACCINES MARKET FOR DNA VACCINES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 20.TOTAL NUMBER OF PETS OWNED IN THE U.S. (IN MILLIONS)
  • FIGURE 21.ANIMAL VACCINES MARKET FOR DOGS, 2020-2030 ($MILLION)
  • FIGURE 22.ANIMAL VACCINES MARKET FOR CATS, 2020-2030 ($MILLION)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 24.ANIMAL VACCINES MARKET FOR CATTLE, 2020-2030 ($MILLION)
  • FIGURE 25.ANIMAL VACCINES MARKET FOR PIGS, 2020-2030 ($MILLION)
  • FIGURE 26.ANIMAL VACCINES MARKET FOR POULTRY, 2020-2030 ($MILLION)
  • FIGURE 27.ANIMAL VACCINES MARKET FOR SHEEP, 2020-2030 ($MILLION)
  • FIGURE 28.ANIMAL VACCINES MARKET FOR HORSES, 2020-2030 ($MILLION)
  • FIGURE 29.ANIMAL VACCINES MARKET FOR OTHERS, 2020-2030 ($MILLION)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF LIVESTOCK ANIMAL VACCINES MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 31.COMPARATIVE SHARE ANALYSIS OF AQUACULTURE ANIMAL VACCINES MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 32.BOEHRINGER: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 33.BOEHRINGER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 34.BOEHRINGER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 35.MERCK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.MERCK: REVENUE SHARE BY PRODUCT, 2020 (%)
  • FIGURE 37.MERCK: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 38.SANOFI: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 40.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 41.VIRBAC: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 42.VIRBAC: REVENUE SHARE BY PRODUCT CATEGORY, 2020 (%)
  • FIGURE 43.VIRBAC: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 44.ZOETIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 45.ZOETIS: REVENUE SHARE BY PRODUCT, 2020 (%)
  • FIGURE 46.ZOETIS: REVENUE SHARE BY REGION, 2020(%)